analyses was 34% in low-grade lymphoma and only 8% in intermediate-grade lymphoma. Clonal Ig gene rearrangements were detected nearly universally in the small lymphocytic histologic subtype. PBL studies were related to the initial stage of disease: positive studies were seen in 35% of patients with stage IV disease, 29% of patients with stage 111 disease, and 12% of patients with stages [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] disease. The incidence of PBL rearrangements at the time of disease recurrence in 32 patients requiring cytoreductive therapy was 48%. somewhat greater than at initial diagnosis. A group of patients with low-grade lymphoma, HE ELUCIDATION of the structure of the immuno-T globulin (Ig) genes and the genes that encode the T-cell receptor affords a genotypic alternative to conventional morphologic and immunophenotypic methods for diagnosing lymphoid malignancies.' Early in the course of differentiation, cells of B-lymphocyte lineage rearrange their Ig genes, and the specific configuration of a rearrangement is unique to the individual B cell containing that gene and any clonal descendants of that gene.2 Similarly, the T-cell receptor genes undergo rearrangement during early T-cell development.3-8 Based on this principle, analyses of clonal Ig gene rearrangements and T-cell receptor rearrangements using DNA hybridization have been applied to the diagnosis of lymphoid neoplasms. Advantages of this technique include the requirement for only a small number of cells (about IO6), the ability to detect neoplastic cells as low as 1% of the total cell population, and the applicability to B-cell tumors lacking surface or cytoplasmic Ig and T-cell
We have reported on the detection of B-cell lymphoma in the peripheral blood by DNA hybridization in a small group of patients, including both those with active disease and those in remission. '6 Among the potential applications of this convenient and sensitive means for detecting lymphoma from the blood are initial staging, determination of the effectiveness of therapy, and detection of recurrent disease. Results of our preliminary work prompted us to begin a large-scale study in non-Hodgkin's lymphoma in March 1986 with the following objectives: (1) to assess the incidence of gene rearrangements in the peripheral blood according to histology, stage, and disease status, and (2) to correlate results with additional clinical and pathologic observations such as disease recurrence, histologic transformation, spontaneous regression, and discordant histologic subtypes.
PATIENTS AND METHODS
Mononuclear cells were isolated from 20 mL peripheral blood using Ficoll-Paque (Pharmacia, Piscataway, NJ) sedimentation. Five to ten micrograms of purified DNA were digested with who had treatment deferred after diagnosis or recurrence, was also studied; the incidence of PBL rearrangements was 38% in this population. Among 157 patients clinically free of disease, DNA analyses of the PBL were positive in only 10%. Subsequent relapse of disease in 26 patients was antedated by PBL rearrangement in only one patient. Clonal rearrangements detected in 15 patients have been followed by recurrence of clinical disease in only one patient over a median of 24 months from the time of analysis. The lack of detectable rearrangements in the peripheral blood in the majority of patients may be due to methodology or the biology of the disease. These issues may be further addressed with alternative methods for assessment of minimal disease. However, rigorous testing of any new molecular tool requires an adequate patient population in which disease status is closely monitored over a sufficient period of time. 0 1990 by The American Society of Hematology.
appropriate restriction enzymes under the conditions recommended by the suppliers. DNA fragments were fractionated according to size in 0.8% agarose gels and were transferred onto activated nylon membranes (Genatran 45; Plasco, Inc, Woburn, MA), according to the method of Southern." The membranes were then baked, prehybridized, hybridized, and washed as previously described.' The DNA probes were radiolabeled by the hexamer primer method."
The structure of these probes has been previously de~cribed.'*'~.*~ In brief, the JH probe is specific for the joining regions of the heavy chain Ig DNA regardless of expressed heavy chain class. The light chain probes contain the kappa constant region and combined lambda constant regions. The T-cell probe is a combination of JB, and JBz fragments. BamHl and EcoRl restriction enzymes were used for the J heavy chain analyses; BamHl and BglII were used for the T beta probe; BamHl was used for the kappa chain analyses; and EcoRl was used for the lambda light chain analyses. Periodic controls confirmed the 1% level of sensitivity of the light chain gene rearrangement analyses; sensitivity with the heavy chain probe is about 2.5%. (BglII digests have subsequently proved to be more sensitive in the detection of J, rearrangements but did not add to the sensitivity of kappa/lambda analyses.)
Peripheral blood smears were analyzed in the clinical laboratory of Stanford University Hospital (Stanford, CA). Differential white blood counts were determined on counting a minimum of 100 cells of Giemsa-stained blood smears.
The schema ( subtypes at diagnosis as part of initial staging and restaging to determine remission status at the completion of treatment, and annually thereafter. Additional studies were done to determine the prevalence of rearrangements in the peripheral blood in patients who were being followed without therapy. Patients considered to be in clinical remission (free of disease) with low-grade NHL were studied at 2 to 48 months, and more than 84 months after therapy to correlate results with expected occult disease. Intermediate and high-grade lymphoma patients were studied at less than or greater than 24 months after treatment to determine if peripheral blood analyses correlated with continued freedom from disease or predicted relapse. The prevalence of peripheral blood rearrangements was also studied in indolent, untreated low-grade NHL at 2 to 48 months and greater than 84 months after diagnosis. Standard management policies for each histologic subtype and stage were followed during the course of this study.
RESULTS
Peripheral blood was analyzed in 104 patients a t diagnosis and rearrangements were found in 27, or 26% ( Table 2 ). The incidence of rearrangements was 34% among low-grade lymphoma patients, including 31% of those with follicular small cleaved (FSC) lymphoma and 23% of those with follicular mixed (FM) subtypes. Eight of 10 patients with small lymphocytic (SL) lymphoma had rearrangements detected in the peripheral blood. Neither of two patients with "other" (monocytoid B-cell lymphoma) low-grade lymphoma had a rearrangement in the peripheral blood.*'
Only three of 39 (8%) peripheral blood samples demonstrated clonal Ig or T-cell receptor gene rearrangements in intermediate-grade lymphoma patients a t diagnosis. None had circulating lymphoma cells identified by morphologic evaluation, and bone marrow biopsies were negative by light microscopy in 2 of the 3 patients with positive analyses. There was a discordance in histology in the single case with positive histology in the bone marrow: the peripheral lymph node demonstrated follicular large cell lymphoma and the bone marrow contained small cleaved cells. Four of 11 patients with high-grade lymphoma had positive peripheral blood analyses, including 1 patient with Burkitt's lymphoma, 1 with diffuse small noncleaved cell (non-Burkitt's), and 2 of 5 cases of T-cell lymphoma. Both T-cell patients with positive studies had involvement of the skin. None of the high-grade cases had circulating lymphoma cells, and only one (Burkitt's lymphoma) had a positive bone marrow biopsy by routine histologic analysis. Three gene rearrangement studies were performed in patients with lymphoma that could not be further classified; in the single positive case the patient had no known residual disease after diagnostic splenectomy.
The incidence of gene rearrangements in the peripheral blood in patients at diagnosis was influenced by the stage of disease as described in Table 3 . Seventeen (35%) of the 49 patients with stage IV disease had rearrangements. Among the stage IV cases, the incidence of detectable circulating lymphoma cells was highest in the subgroup of patients with morphologically positive bone marrow biopsies: 15 of 33 (45%). Of these 15, circulating tumor cells were identified by morphology in four patients, and two patients had a relative lymphocytosis. Rearrangements were also noted in 6 (29%) of 21 patients with stage 111 disease, all of whom had negative bone marrow biopsies. Rearrangements were uncommon (12%) among patients with limited, stage I or stage I1 disease. The apparent difference in incidence of positive gene rearrangement studies between intermediate and high-grade lymphoma may be partially explained by the fact that 19 of 39 patients with intermediate-grade lymphoma had limited disease compared with only 3 of 1 I patients with high-grade lymphoma. However, morphologic grade remains an important determinant of positive analyses after correction for stage and marrow histology.
A second group of patients with clinical disease, those with Peripheral blood rearrangements were also studied in a third group of patients with clinical disease consisting of 42 low-grade lymphoma patients managed with deferred therapy. Positive studies were noted in 16 (38%), including 27% of FSC, 29% of FM, and 78% of SL.
Correlation of gene rearrangement results with PBL morphology for patients studied at diagnosis, on recurrence, and for those in whom treatment was deferred is described in Table 4 . Morphologic examination of the peripheral blood smear showed lymphoma cells in 10 of 57 positive cases. The positive cases at diagnosis all occurred in patients with FSC lymphoma. Five patients with SL lymphoma had an absolute lymphocyte count greater than 3,000/mm3 at diagnosis; all had positive peripheral blood studies. All of the patients with a positive peripheral blood smear at the time of disease recurrence had low-grade lymphoma. No patient with intermediate-or high-grade lymphoma had morphologic evidence of circulating lymphoma cells. Table 5 describes the results of PBL gene rearrangement analyses in 157 patients who were in clinical remission, free of evident disease. Rearrangements were detected in only 6 of 63 (10%) patients with low-grade lymphoma. All rearrangements were detected between 2 and 48 months after treatment. Nineteen of the 63 patients subsequently developed recurrent disease, only one of whom had a rearrangement in the peripheral blood before relapse. The median time from DNA analysis to relapse was 10 months (range 0 to 27 months). In the intermediate-and high-grade categories, 9 of 94 patients (10%) with no evident disease had clonal rearrangements detected in the peripheral blood. Among the seven relapses in the intermediate-and high-grade categories, none was preceded by a positive peripheral blood study. Relapses in the intermediate-and high-grade lymphomas occurred a median of 3 months after peripheral blood analysis. No relapses occurred in this group more than 2 years after therapy. The entire group of 157 patients in clinical remission at the time of study has been followed a median of 24 months from the time of DNA analyses to the last follow-up. Summarizing the statistics mentioned above, 14 of the 15 patients with circulating lymphoma cells as detected by gene rearrangement analyses have not yet manifested clinical disease.
While the DNA hybridization technique yields a qualitative rather than a quantitative result, rearrangements were scored as "major" when they were at least as prominent as Time from analysis to last the germline, and "minor" when they were less prominent. A panel of representative clonal bands from patients without clinical disease can be seen in Fig 1. Examples of major and minor clones are illustrated, including those from one patient who first had a major band and, 1 year later, an identical minor band detected by the lambda probe. The single patient who relapsed after a positive PBL study had both kappa and lambda rearrangements; the subsequent tissue biopsy shows kappa light chain restriction. Figure 1 also shows major add minor bands detected by the J, and kappa probes.
Rearrangements in the 72 positive cases were further analyzed according to intensity (major and minor) and the probes detecting clonality (Fig 2) . Of the 33 major rearrangements, 16 cases were kappa and 14 cases were lambda, with one case showing rearrangements of both kappa and lambda genes. Only one major band was detected by the J, probe alone. In contrast, the majority of minor bands were detected by the J, probe only. Figure 2 describes the number of major and minor gene rearrangements detected according to probe and clinical status. Patients without clinical disease were likely to have a less-intense clonal band compared with patients with active disease, especially if recurrent.
Throughout the study, identical patterns of rearranged genes were seen in our patients whenever multiple tissues were tested. Furthermore, these patterns did not change over time, indicating that these lymphomas represent monoclonal processes with stable rearrangements of antigen receptor genes.
DISCUSSION
DNA hybridization has proven to be useful in the diagnosis of neoplasms without definitive histologic or phenotypic features.'.'' The optimal sensitivity of detecting neoplastic cells, about 1 to 2 in 100, is a 10-fold improvement over methods using clonal e x c e s~.~~'~' In addition, in contrast to the method of clonal excess, Southern analysis can be applied to lymphomas lacking expression of light chain and to T-cell lymphomas. An early study from our group found genotypic evidence of B-cell lymphoma in the peripheral blood in 22 of 29 (76%) patients with low-grade lymphoma.'6 Only six had circulating cells detected by routine morphology. Seventeen of these 29 patients were receiving chemotherapy, of whom 15 had positive PRL studies. However. clonal rcarrangements were also noted in 7 of 12 patients felt to be in clinical remission.
The current study finds the incidence of PRL gene rearrangements to be considerably less. Possible explanations for this difkrence include patient selection. the influence of chemotherapy. or technical factors inherent in expansion of these analyses to a large group of patients. Each of the blots in the current study was reviewed by two of the authors (M.C.. J.S.). who independently arrived at similar interprctations. However. among factors that may have afTected the results of this study compared with the earlier one include ( I ) analyses from lymph node tissue were available for comparison of clonal bands from more patients in the earlier study. possibly aiding in the detection of faint bands; (2) all of the patients in the initial study had low-grade histology and the majority had advanced disease; and (3) the initial study consisted mainly of patients with recurrent disease who were receiving chemotherapy. In the current analysis, patients with disease recurrence werc somewhat more likely to have positive studies than patients at the time of original diagnosis.
Rrada et al?' publishcd the results of DNA hybridimtion in PRI. from SO patients. treated and untreated. with a variety of histologic subtypes of non-Hodgkin's lymphoma. Nineteen (38%) had a circulating clonal population as detected by J,, and J, DNA probes. I n agreement with our current study. thc incidence of PRL involvement was greater in advanced disease (54%) in contrast with limited disease (187). and in low-grade lymphoma (45%) versus intermediate/high-grade lymphoma (31'7).
Ig gene rearrangement analyses were also applied to the peripheral blood by Berliner et al." who looked at I 7 case5 of B-cell lymphoma (histology unspecified) and 13 caws of R-cell leukemia. Their rcsults primarily confirmed that the detection of kappa/lambda light chain imbalance reflccted a patients in an earlier study from the Boston group.'' Many of thee patients were studied later in the course of their disease and this may explain the high incidence of positive studics.
However. 16 (647) of 25 patients with FSC lymphoma in remission also had PRL clonal excess. This contrasts with an incidence of only 10% of 63 patients in our series. including 3 of 8 patients who had bccn treated more than 7 years earlier.
Given the technical comparisons of the methods made by Berliner et al." the differences in results must be related to patient selection or the extent to which patients referred to as disease-free are evaluated for recurrent disease.
Our study was designed to assess the incidence of circulating lymphoma cells by gene rearrangement analyses in n large group of patients representing multiple categories of disease activity and histology, including many cases in which clinical disease was either extremely indolent or not apparent. Circulating lymphoma cells were not detected by DNA hybriditation in the majority of patients with non-Hodgkin's lymphoma. This was particularly true in patients with intermediate-grade. diffuse large cell histology. Circulating lymphoma cells were rarely detected in patients with limitedstage disease, regardless of histology. Thcsc results suggest that the number of tumor cells in the blood at diagnosis in these clinical situations is extremely low or nonexistent. In contrast. 30% of patients with follicular small cleaved cell lymphoma and the majority of patients with small Iymphocytic lymphoma had circulating tumor cells at diagnosis. Although the majority had histologic evidence of bone marrow involvement with lymphoma. few had lymphoma cells in the peripheral blood by morphologic asscssment. indicating the increased sensitivity of the gene rearrangemcnt analyscs. Peripheral blood gene rearrangements were more common on disease recurrence. This is not unexpected as most lymphomas become more widely disseminated on recurrence.
The most surprising finding in our study was 
